Working with Regulatory Consultants and Managing the FDA Relationship

Regulatory consultants are a category of professional that founders routinely underhire for and overpay the wrong ones. The field ranges from former FDA reviewers with deep submission experience in specific device categories to generalists who produce templated documents that FDA has seen hundreds of times. The difference is not always obvious from a website or a proposal. Hiring the wrong consultant at the wrong stage is not just expensive — it can mean a submission that fails for reasons a better consultant would have caught in week one.

The most important qualification to look for in a regulatory consultant is category-specific experience — meaning experience with the specific FDA product code, device type, and clinical indication that applies to your product. FDA review is highly specialized. A consultant who has shepherded twelve 510(k) submissions through the Orthopedic and Rehabilitation Devices branch may have no useful experience with the Clinical Chemistry and Toxicology branch. Ask every consultant candidate which submission types they have completed in the last three years, which FDA review divisions they worked with, and whether any of those submissions received major deficiencies. Ask for redacted examples.

Former FDA employees — called FDA alumni — are disproportionately represented in regulatory consulting. Their value is real but often misunderstood. A former reviewer brings insight into how FDA evaluates submissions in their former division, what common deficiencies look like, and what language FDA responds well to. What they do not bring is the ability to leverage personal relationships to influence a review. The FDA review process is documented and sequential, and the idea that knowing someone at FDA creates a shortcut is a misconception that leads founders to overpay for the wrong kind of experience.

The FDA relationship begins long before a formal submission is filed. Pre-submission interactions — through Q-Subs, Type A, B, and C meetings for drug and biologic sponsors, and informal meetings for device companies — are the primary instrument for aligning your development program with FDA expectations. Every interaction with FDA should be treated as part of a durable record. FDA maintains detailed notes on sponsor interactions, and the content of those exchanges affects how reviewers interpret your formal submissions. Positions taken in pre-submission meetings that contradict the formal submission create credibility problems that are very difficult to recover from.

Regulatory submissions are formal legal documents, not persuasive essays. The goal of a 510(k) or PMA is not to make a compelling case — it is to provide the specific evidence and analysis FDA requires in the format FDA expects, clearly enough that the reviewer does not have to ask follow-up questions. Deficiency letters — formally called Additional Information requests in device submissions — are issued when a reviewer cannot resolve a question from the submission itself. Every AI request pauses the review clock, but more importantly it signals that the submission was not complete, which colors how the reviewer approaches everything that follows.

Responding to deficiency letters requires a different skill than writing the original submission. The response must address every question directly, provide specific evidence, and avoid creating new questions in the process. A common mistake is to respond to a deficiency by adding hedging language, providing more studies than requested without clear organization, or restating claims without addressing the underlying concern. The FDA reviewer reads hundreds of deficiency responses. Organized, direct responses that give the reviewer exactly what they need to close the question move faster than comprehensive responses that bury the answer.

The Office of Combination Products is worth understanding separately for any product that combines a drug, device, and biologic — such as a drug-eluting stent, a prefilled syringe, or a diagnostic device that incorporates a biological reagent. Combination products are assigned to a primary FDA center based on the mode of action, but the regulatory requirements from the non-primary centers still apply. Companies building combination products often need regulatory consultants with experience spanning multiple FDA centers, which is a rare and expensive skill set.